Cita APA (7a ed.)
Tao, H., Chen, J., Lv, D., Wang, J., Ma, J., Yi, T., . . . Hu, Y. (2026). Efficacy and safety of surufatinib plus PD-1/PD-L1 inhibitors as first-line maintenance therapy in extensive-stage small cell lung cancer. Holistic Integrative Oncology, 5(1), 1-11.
Cita Chicago Style (17a ed.)
Tao, Haitao, et al. "Efficacy and Safety of Surufatinib Plus PD-1/PD-L1 Inhibitors as First-line Maintenance Therapy in Extensive-stage Small Cell Lung Cancer." Holistic Integrative Oncology 5, no. 1 (2026): 1-11.
Cita MLA (9a ed.)
Tao, Haitao, et al. "Efficacy and Safety of Surufatinib Plus PD-1/PD-L1 Inhibitors as First-line Maintenance Therapy in Extensive-stage Small Cell Lung Cancer." Holistic Integrative Oncology, vol. 5, no. 1, 2026, pp. 1-11.
Precaución: Estas citas no son 100% exactas.